首页> 外文OA文献 >Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: A full in vitro analysis
【2h】

Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: A full in vitro analysis

机译:非甾体类药物对环加氧酶-1而非环加氧酶-2的选择性与人类胃肠道毒性有关:全面的体外分析

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The beneficial actions of nonsteroid anti-inflammatory drugs (NSAID) can be associated with inhibition of cyclo-oxygenase (COX)-2 whereas their harmful side effects are associated with inhibition of COX-1. Here we report data from two related assay systems, the human whole blood assay and a modified human whole blood assay (using human A549 cells as a source of COX-2). This assay we refer to as the William Harvey Modified Assay. Our aim was to make meaningful comparisons of both classical NSAIDs and newer COX-2-selective compounds. These comparisons of the actions of >40 NSAIDs and novel COX-2-selective agents, including celecoxib, rofecoxib and diisopropyl fluorophosphate, demonstrate a distribution of compound selectivities toward COX-1 that aligns with the risk of serious gastrointestinal complications. In conclusion, this full in vitro analysis of COX-1/2 selectivities in human tissues clearly supports the theory that inhibition of COX-1 underlies the gastrointestinal toxicity of NSAIDs in man.
机译:非甾体类抗炎药(NSAID)的有益作用可能与环氧化酶(COX)-2的抑制有关,而其有害的副作用与COX-1的抑制有关。在这里,我们报告来自两个相关测定系统的数据,即人全血测定和改良的人全血测定(使用人A549细胞作为COX-2的来源)。我们称此测定为William Harvey改良测定。我们的目的是对经典的NSAID和较新的COX-2选择性化合物进行有意义的比较。这些对> 40种非甾体抗炎药和新型塞洛昔单抗,罗非考昔和氟磷酸二异丙酯的新型COX-2选择性药物作用的比较表明,化合物对COX-1的选择性分布与严重胃肠道并发症的风险相吻合。总之,对人体组织中COX-1 / 2选择性的完整体外分析清楚地支持了这样一种理论,即COX-1的抑制是NSAIDs对人胃肠道毒性的基础。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号